Ant Karaduman joins  ELAA Technology in his capacity as Chief Technology Officer


ELAA Technology,a digital health company developing solutions for cancer early diagnosis, announces the appointment of Ant Karaduman as Chief Technology Officer as from July, 2020.


“We have successfully passed human trials and received our CE certification for our lung cancer device PRECIMON™️ in April this year and currently focusing on commercializing PRECIMON™️ in UK and Europe markets. We are committed to provide state of the art "Software as a Medical Device" solutions to community. In line of this vision, we have just started to study on a diagnostic device candidate on a rare disease called “Idiopathic Pulmonary Fibrosis" as well as keeping our good work on colorectal and prostate cancer indications.  In that manner, Ant is bringing in a priceless experience we sorely need by setting up our technical capabilities in a way to be commercially viable while enhancing our security posture. Ant’s ability and experience on product commercialization, architectural design and cyber security will enable us to well position ourselves in the market.  With our eyes set on a HI-TRUST certification to show our commitment to security and privacy, Ant will also lead our roadmap to GDRP & KVKK & UK Data Protection Act and HIPAA compliances. As we have recently started operations in our Manchester (UK) office, Ant's expertise on global services and infrastructures will let us easily extend our service coverage to any country easily.” Said Dr.Tunç Laçin, Co-Founder and Chairman of ELAA Technology.


“I am delighted to become a part of ELAA Technology team and can’t wait to see PRECIMON™️ making a huge impact as well as all the new "life touching" ideas coming up as great products with this great team. This year we will focus more on security, privacy and long term strategy setup to be ready for rapid global growth“ commented Mr.Ant Karaduman, Chief Technology Officer of ELAA Technology

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.    OK   Learn More